Get an alert when CONSORT MEDICAL LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2026-11-24 (in 6mo)

Last made up 2025-11-10

Watchouts

None on the register

Cash

£3M

+106,933.3% vs 2023

Net assets

£226M

+12.6% vs 2023

Employees

0

Average over period

Profit before tax

-£11M

-208.3% vs 2023

Accounts

2-year trend · latest reflected 2024-12-31

Metric Trend 2023-12-312024-12-31
Turnover
Operating profit £10,754,000-£10,626,000
Profit before tax £10,613,000-£11,499,000
Net profit £10,892,000-£10,047,000
Cash £3,000£3,211,000
Total assets less current liabilities £200,925,000£226,253,000
Net assets £200,925,000£226,253,000
Equity £200,925,000£226,253,000
Average employees 00
Wages

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2023-12-312024-12-31
Return on capital employed 5.4%-4.7%
Gearing (liabilities / total assets) 38.3%16.5%
Current ratio 0.04x0.14x
Interest cover 1.34x-1.22x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
FRS 101
Reporting scope
Standalone (parent only)
Auditor
Ernst & Young LLP
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“the directors are confident that the company will have sufficient funds to continue to meet its liabilities as they fall due for the review period to 31 December 2026 and therefore have prepared the financial statements on a going concern basis.”

Group structure

  1. CONSORT MEDICAL LIMITED · parent
    1. Consort Medical Holdings Limited 100% · UK · Holding company
    2. Aesica Queenborough Ltd 100% · UK · Pharmaceutical ingredients/products manufacturer
    3. Consort Medical Srl 100% · Italy · Holding company
    4. Aesica Pharmaceuticals SRL 100% · Italy · Finished dose drug manufacture and packaging
    5. Consort Medical GmbH 100% · Germany · Holding company
    6. Aesica Pharmaceuticals GmbH 90% · Germany · Pharmaceutical products/packaging manufacturing

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

3 active · 58 resigned

Name Role Appointed Born Nationality
DAWSON, Andrew Robert Anthony Director 2023-02-01 Jan 1980 British
GRAND, Emmanuel Nicolas Director 2024-04-01 Feb 1974 Swiss
HOLLOWAY, Guenaelle Director 2024-04-01 Nov 1973 French
Show 58 resigned officers
Name Role Appointed Resigned
ALLNUTT, Robert Edward Bruce Secretary 2009-02-27 2009-10-30
COTTON, Richard John Secretary 2014-04-30 2014-07-15
HAYES, Paul Andrew Secretary 2018-02-28 2018-09-07
ILETT, John Edward Secretary 2015-11-02 2018-02-28
JACKSON, Andrew Leonard Secretary 2018-09-07 2020-04-30
KERBEY, David Terence Secretary 1997-07-01
LOBO, Matthew Joseph Edwin Secretary 2005-10-01 2006-03-08
OWEN, Jennifer Margaret Secretary 2006-03-08 2009-02-27
SAUNBY, Tracy Secretary 2020-04-30 2020-07-31
SCOTT, Alexandra Louise Secretary 1997-07-01 2005-09-30
SLATER, John Secretary 2009-11-02 2014-04-30
WARD, Iain Stuart Secretary 2014-07-15 2015-11-02
ALTMAN, William P Director 1993-09-24 1998-01-31
AUER, Adrian Richard Director 2005-04-01 2006-04-26
BANKS, Christopher John Director 2006-04-26 2012-08-30
BARR, Robert George Director 1996-04-29 1999-10-29
BOUGHTON, Paul Victor Director 2006-06-01 2009-12-10
BRINSMEAD, Christopher David Director 2019-02-07 2020-02-04
CASHMAN, John Patrick Director 2002-09-20 2006-09-28
CHAMBRE, Peter Alan Director 1994-03-09 2000-07-29
CHISHOLM, John Alexander Raymond, Sir Director 1999-09-10 2005-09-08
COOKSEY, David James Scott, Sir Director 1993-12-21 2004-01-20
COTTON, Richard John Director 2012-06-25 2016-12-13
CRUMMETT, Stephen Paul Director 2012-06-13 2020-02-04
DICK, James Lawrence Director 2006-04-26 2012-08-30
DRUMMOND, Lynn, Dr Director 2011-02-09 2014-07-14
DUNNE, Patrick Joseph Director 1996-03-29
ELDERED, Thomas Bengt Director 2020-02-04 2021-03-15
FELLNER, Peter John, Dr Director 2005-11-14 2019-04-24
FITZWILLIAMS, Duncan John Lloyd Director 1999-09-10
GINMAN, Maria Charlotta Director 2015-02-11 2020-02-04
GLENN, Jonathan Martin Director 2006-09-11 2020-02-04
HAYES, Paul Andrew Director 2017-05-01 2020-02-04
HICKS, Alun George Director 1994-09-23
HIGGINS, Nicolas Andrew Director 2011-01-01 2013-02-28
HILAIRE, Jean-Francois Director 2021-03-15 2022-11-01
HIRST, Christopher Anthony Director 2022-11-01 2024-04-01
HOPCROFT, Martin Peter Director 2002-11-05 2006-07-26
HOSTY, Andrew Joseph, Dr Director 2014-07-14 2020-02-04
JENKINS, William John, Dr Director 2009-05-06 2020-02-04
KENNEDY, George Macdonald Director 2006-08-29 2011-09-01
KING, Robert Harmer Director 1995-09-06
KLUG, Oren Director 2022-03-15 2024-04-01
LILLEY, John Director 1996-05-31
LODGE, Lisa Director 2022-05-06 2023-02-01
MANN, Roger Director 1997-01-31 2001-09-21
MEREDITH, William George Director 2000-07-04 2006-09-28
NICHOLSON, Ian James Director 2012-06-13 2020-02-04
PREECE, Robert John Director 1995-04-03 2002-11-05
QUICK, Mark Royston Director 2020-02-04 2022-03-15
ROBINSON, John Harris Director 2004-01-20 2009-04-30
ROXIN, Daniela Sylvia Beate, Dr. Director 2021-05-01 2022-11-01
SCHUMANN, Andrew Anthony Director 2000-09-22
SCHUMANN, Michael Alec Director 1993-09-01
TALBOT, Michael Alan Director 1999-04-30
TAYLOR, Paul Director 2000-07-04 2002-07-31
THRODAHL, Mark Crandall Director 2001-06-07 2007-12-05
WOOLRYCH, Toby Richard Director 2008-10-01 2012-06-25

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Recipharm Uk Limited Corporate entity Shares 75–100%, Voting 75–100%, Appoints directors 2020-03-06 Active

Filing timeline

Last 20 of 582 total filings

Date Type Category Description
2025-12-19 AA accounts Accounts with accounts type full
2025-12-09 PSC05 persons-with-significant-control Change to a person with significant control PDF
2025-11-17 CS01 confirmation-statement Confirmation statement with updates PDF
2025-06-24 SH19 capital Capital statement capital company with date currency figure
2025-06-24 SH20 capital Legacy
2025-06-24 CAP-SS insolvency Legacy
2025-06-24 RESOLUTIONS resolution Resolution
2025-03-20 CS01 confirmation-statement Confirmation statement with updates PDF
2024-12-06 AD01 address Change registered office address company with date old address new address PDF
2024-08-12 AA accounts Accounts with accounts type full
2024-04-22 SH01 capital Capital allotment shares
2024-04-09 AP01 officers Appoint person director company with name date PDF
2024-04-09 AP01 officers Appoint person director company with name date PDF
2024-04-09 TM01 officers Termination director company with name termination date PDF
2024-04-09 TM01 officers Termination director company with name termination date PDF
2024-04-09 MR04 mortgage Mortgage satisfy charge full PDF
2024-04-03 MR04 mortgage Mortgage satisfy charge part PDF
2024-03-15 CS01 confirmation-statement Confirmation statement with no updates PDF
2023-10-16 AA accounts Accounts with accounts type full
2023-03-10 CS01 confirmation-statement Confirmation statement with no updates PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
7

last 12 months

Capital events
2

last 24 months

Officers appointed
0

last 12 months

Officers resigned
0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers

Official Companies House page